Get Live Data

We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE
Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses
Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licensesView Video

Latest Share Chat

  2. Share Prices
  3. Synairgen Share Price
  4. Synairgen Share Regulatory News
  5. Holding(s) in Company

Pin to quick picksSynairgen Regulatory News (SNG)

Synairgen Information

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.59
Bid: 6.20
Ask: 6.98
Change: 0.19 (2.97%)
Spread: 0.78 (12.581%)
Open: 6.40
High: 0.00
Low: 0.00
Prev. Close: 6.40
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 Nov 2020 17:03

RNS Number : 3364F
Synairgen plc
13 November 2020
 

Synairgen plc

("Synairgen" or the "Company")

Holding(s) in Company

 

Southampton, UK,: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it was informed on 13 November 2020 that Leonard Licht, a private investor, now holds less than 3% of the Company's issued share capital.

Enquiries:

Synairgen plc +44 (0) 23 8051 2800

Richard Marsden (Chief Executive Officer)

John Ward (Finance Director)

finnCap - Nominated Adviser and Joint Broker +44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)

Alice Lane / Sunila de Silva (ECM)

Numis - Joint Broker +44 (0) 20 7260 1000

James Black / Freddie Barnfield / Duncan Monteith

Consilium Strategic Communications - Financial Media and Investor +44 (0) 20 3709 5700

Relations Adviser

Mary-Jane Elliott / Sue Stuart / Olivia Manser

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFLFIDLFLVLII
12345678910
Date   Source Headline
15th Nov 20237:00 amRNSGrant of Options
11th Oct 20237:00 amRNSAppointment of New Chief Financial Officer
3rd Oct 20237:00 amRNSAppointment of Chief Medical Officer
21st Sep 20237:00 amRNSInterim Results
29th Jun 20236:02 pmRNSResult of AGM
29th Jun 202310:00 amRNSAnnual General Meeting Presentation
22nd Jun 20237:00 amRNSGrant of Options
23rd May 20237:00 amRNSPosting of Annual Report and Notice of AGM
27th Apr 20237:00 amRNS2022 Full Year Results
17th Apr 20237:00 amRNSNotice of Full Year results
13th Mar 20234:40 pmRNSSecond Price Monitoring Extn
13th Mar 20234:35 pmRNSPrice Monitoring Extension
3rd Feb 20234:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 20234:40 pmRNSSecond Price Monitoring Extn
13th Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Dec 202211:30 amRNSSPRINTER Trial Results Published
14th Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSBoard Changes
7th Nov 20224:40 pmRNSSecond Price Monitoring Extn
7th Nov 20224:35 pmRNSPrice Monitoring Extension
3rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
3rd Nov 20224:35 pmRNSPrice Monitoring Extension
20th Oct 20224:35 pmRNSPrice Monitoring Extension
6th Oct 20221:35 pmRNSHolding(s) in Company
4th Oct 20227:02 amRNSData from the US NIH-led ACTIV-2 Phase 2 trial
29th Sep 20227:01 amRNSBoard Changes
29th Sep 20227:00 amRNSInterim Results
20th Sep 20227:00 amRNSSPRINTER Long COVID data presented at IDWeek
15th Sep 20227:00 amRNSNotice of Interim Results
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:35 pmRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSPositive Findings from SG015 Tri-al Analysis
5th Sep 20227:00 amRNSCompany Announce Collaboration on UNIVERSAL Trial
6th Jul 20227:00 amRNSGrant of Options
30th Jun 20221:45 pmRNSResult of AGM
23rd Jun 20224:40 pmRNSSecond Price Monitoring Extn
23rd Jun 20224:35 pmRNSPrice Monitoring Extension
15th Jun 20222:30 pmRNSHolding(s) in Company
9th Jun 20223:00 pmRNSExercise of Options and Total Voting Rights
6th Jun 20224:25 pmRNSPosting of Annual Report & Notice of AGM
25th May 20227:00 amRNSFull Year Results
18th May 20224:36 pmRNSPrice Monitoring Extension
16th May 20227:00 amRNSSynairgen presents at ATS 2022
25th Apr 20227:00 amRNSPresentation at ECCMID
19th Apr 20224:40 pmRNSSecond Price Monitoring Extn
19th Apr 20224:35 pmRNSPrice Monitoring Extension
6th Apr 20222:10 pmRNSHolding(s) in Company
5th Apr 20227:00 amRNSSynairgen to present at ATS 2022
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.